Oral estrogen replacement therapy versus placebo for hot flushes: a systematic review

References

• Freedman RR, Norton D, Woodward S, Cornelissen G. Core body temperature and circa-dian rhythm of hot flashes in menopausal women. J Clin Endocrinol Metab 1995;80: 2354–8
   PubMed Web of Science ®Google Scholar
• Porter M, Penney GC, Russell D, Russell E, Templeton A. A population based survey of women's experience of the menopause. Br J Obstet Gynaecol 1996;103:1025–8
   Google Scholar
• Mohyi D, Tabassi K, Simon J. Differential diag-nosis of hot flashes. Maturitas 1997;27:203–14
   Google Scholar
• Sturdee D, Brincat M. The hot flush. In Studd JWW, Whitehead MI, eds. The Menopause. London: Blackwell Scientific, 1988:24–42
   Google Scholar
• The Women's Health Initiative Study Group. Design of the Women's Health Initiative clinical trial and observational study. Control Clin Trials 1998;19:61–109
   Google Scholar
• MacLennan AH, Paine BJ, Marley JE. Australian women's likelihood of participation in WISDOM. Aust Fam Physician 2000;29:1–5
   Google Scholar
• DerSimonian R, Laird N. Meta-analysis in clini-cal trials. Control Clin Trials 1986;7:177–88
   PubMedGoogle Scholar
• Baujat B, Mahe C, Guerin S, Pignon J-P. Detec-tion of outlying and influential trials: a graphical method to explore heterogeneity in meta-analysis. Presented at the VII Cochrane Collo-quium. The best evidence for health care: the role of the Cochrane Collaboration. Rome, October 1999
   Google Scholar
• Thompson SG, Sharp S. Explaining heterogeneity in meta-analysis: a comparison of methods. Stat Med 1999;18:2693–708
   PubMed Web of Science ®Google Scholar
• Whitehead A, Bailey AJ, Elbourne D. Combining summaries of binary outcomes with continuous outcomes in a meta-analysis. J Biopharm Stat 1999;9:1–16
   Google Scholar
• Whitehead A, Jones NM. A meta-analysis of clinical trials involving different classifications of response into ordered categories. Stat Med 1994;13:23–4
   PubMedGoogle Scholar
• Blumel JE, Roncagliolo ME, Gramegna G, Vasquez R, Estartus AT. Estudio doble ciego del efecto sobre la sintomatologia menopausica, et perfil lipidico y el grosor endometrial de una terapia continua de valerato de estradiol mas acetato de medroxiprogesterona [Double blind method of the effect of menopause symptoms, lipid profile, and endometrial thickness of con-tinuous therapy with estradiol valerate and medroxyprogesterone acetate]. Rev ail Obstet Ginecol 1994;59;534–60
   Google Scholar
• Chung TKH, Yip SK, Lam P, Chang AMZ, Haines CJ. A randomized, double-blind, placebo-controlled, crossover study on the effect of oral oestradiol on acute menopausal symp-toms. Maturitas 1996;25:115–23
   Google Scholar
• Conard J, Basdevant A, Thomas J-L, et al. Cardiovascular risk factors and combined estrogen—progestin replacement therapy: a placebo-controlled study with nomegestrel acetate and estradiol. Fertil Steril 1995;64: 957–62
   Google Scholar
• Archer DR, Fischer LA, Rich D, et al. Estrace vs. Premarin for treatment of menopausal symp-toms: dosage comparison study. Adv Ther 1992; 9:21–31
   Google Scholar
• Baerug U, Winge T, Nordland G, et al. Do com-binations of 1 mg estradiol and low doses of NETA effectively control menopausal symp-toms? Climacteric 1998;1:219–28
   PubMedGoogle Scholar
• Baumgardner SB, Condrea H, Daane TA, et al. Replacement estrogen therapy for menopausal vasomotor flushes. Comparison of quinestrol and conjugated estrogens. Obstet Gynecol 1978; 51:445–52
   PubMed Web of Science ®Google Scholar
• Bech P, Munk-Jensen N, Obel EB, Ulrich LG, Eiken P, Pors Nielsen S. Combined versus sequen-tial hormonal replacement therapy: a double-blind, placebo-controlled study on quality of life-related outcome measures. P sychother Psychosom 1998;67:259–65
   PubMed Web of Science ®Google Scholar
• Obel EB, Munk-Jensen N, Svenstrup B, et al. A two-year double-blind controlled study of the clinical effects of combined and sequential post-menopausal replacement therapy and steroid metabolism during treatment. Maturitas 1993; 16:13–21
   PubMed Web of Science ®Google Scholar
• Campbell S. Double blind psychometric studies on the effects of natural estrogens on post-menopausal women. In Campbell S, ed. The Management of the Menopause and Post Meno-pausal Years. Lancaster: MTP, 1976:149–55
   Google Scholar
• Campbell S, Whitehead M. Oestrogen therapy and the menopausal syndrome. Clin Obstet Gynecol 1977;4:31–46
   Google Scholar
• Coope J, Thomson JM, Potter L. Effects of 'natural oestrogen' replacement therapy on menopausal symptoms and blood clotting. Br Med J 1975;4:139–43
   Google Scholar
• Coope J. Double blind cross-over study of estro-gen replacement therapy. In Campbell S, ed. The Management of the Menopause and Post Meno-pausal Years. Lancaster: MTP, 1976:159–68
   Google Scholar
• Coope J. Is oestrogen therapy effective in the treatment of menopausal depression? J R Coll Gen Pract 1981;31:134–40
   PubMedGoogle Scholar
• Potter L, Coope J. A double-blind cross-over study of piperazine oestrone sulphate and placebo with coagulation studies. Br J Obstet Gynaecol 1980;87:718–25
   PubMedGoogle Scholar
• Davidsen PCB, Secher HJ, Pedersen GT, Christennnsen N. Sekvensterapi med ostradiol-valerat/norgestrel i klimakteriet [Cyclical therapy with estradiol valerate/norgestrel at the meno- pause. Report of a double-blind investigation]. Ugeskr Laeg 1974;136:1805–8
   PubMedGoogle Scholar
• Dennerstein L, Burrows GD, Hyman GJ, Sharpe K. Hormone therapy and affect. Maturitas 1979;1:247–59
   PubMed Web of Science ®Google Scholar
• Dennerstein LL, Burrows GD, Hyman G. Meno-pausal hot flushes: a double blind comparison of placebo, ethinyl oestradiol and noregestrel. Br J Obstet Gynaecol 1978;85:852–6
   Google Scholar
• Dennerstein L, Fotherby K, Burrows GD, Senior J, Wood C. Hormone replacement therapy at the menopause. Double blind controlled study of women's preferences. NZ J Obstet Gynaecol 1978;18:139–43
   Google Scholar
• Derman RJ, Dawood MY, Stone S. Quality of life during sequential hormone replacement therapy — a placebo controlled study. Int J Fertil Meno-pausal Stud 1995;40:73–8
   Google Scholar
• Hagen C, Christensen M, Christiansen C, Stocklund K-E, Transbol I. Effects of two years' estrogen—gestagen replacement on climacteric symptoms and gonadotropins in the early post-menopausal period. Acta Obstet Gynecol Scand 1982;3:237–41
   Google Scholar
• Christiansen C, Christensen MS, McNair P, Hagen C, Stocklund K, Transbol IB. Prevention of early postmenopausal bone loss: controlled 2-year study in 315 normal females. Eur J Clin Invest 1980;10:273–9
   PubMed Web of Science ®Google Scholar
• Jensen J, Christiansen C. Dose—response and withdrawal effects on climacteric symptoms after hormonal replacement therapy. A placebo-con-trolled therapeutic trial. Maturitas 1985;5: 125–33
   Google Scholar
• Christensen M, Hagen C, Christiansen C, Transbol I. Dose—response evaluation of cyclic estrogen/gestagen in postmenopausal women: placebo-controlled trial of its gynecologic and metabolic actions. Am J Obstet Gynecol 1982; 144:873–9
   PubMed Web of Science ®Google Scholar
• Jensen PB, Jensen J, Riis BJ, Rodbro P, Strom V, Christiansen C. Climacteric symptoms after oral and percutaneous hormone replacement therapy. Maturitas 1987;9:207–15
   PubMed Web of Science ®Google Scholar
• Jensen J, Riis BJ, Christiansen C. Cyproterone acetate, an alternative progestogen in postmeno-pausal hormone replacement therapy? Effects on serum lipids and lipoproteins. Br J Obstet Gynaecol 1987;94:136–41
   Google Scholar
• Christiansen C, Nilas L, Riis BJ, Rodbro P, Deftos L. Uncoupling of bone formation and resorption by combined oestrogen and progesta-gen therapy in postmenopausal osteoporosis. Lancet 1985;2:800–1
   Google Scholar
• Marslew U, Overgaard K, Riis BJ, Christiansen C. Two new combinations of estrogen and progestogen for prevention of postmenopausal bone loss: long-term effects on bone, calcium and lipid metabolism, climacteric symptoms and bleeding. Obstet Gynecol 1992;79:202–9
   PubMed Web of Science ®Google Scholar
• Marslew U, Riis B, Christiansen C. Progestogens: therapeutic and adverse effects in early post-menopausal women. Maturitas 1991;13:7–16
   Google Scholar
• Martin PL, Burnier AM, Segre EJ, Huix FJ. Graded sequential therapy in the menopause: a double-blind study. Am J Obstet Gynecol 1971; 111:178–86
   PubMed Web of Science ®Google Scholar
• Paterson ME. A randomised, double-blind, cross-over study into the effect of sequential mestranol and norethisterone on climacteric symptoms and biochemical parameters. Maturitas 1982;4;83–94
   PubMed Web of Science ®Google Scholar
• Greendale GA, Reboussin BA, Hogan P, et al. Symptom relief and side effects of postmeno-pausal hormones: results from the Postmeno-pausal Estrogen/Progestin Interventions trial. Obstet Gynecol 1998;92:982–8
   PubMed Web of Science ®Google Scholar
• Espeland MA, Bush TL, Mebane-Sims I, et al. for the PEPI trial investigators. Rationale, design and conduct of the PEP! trial. Control Clin Trials 1995;16(Suppl 4):3–19
   Google Scholar
• Miller VT, Byington RL, Espeland MA, et al. Baseline characteristics of the PEP! participants. Postmenopausal Estrogen/Progestin Interven-tions. Control Clin Trials 1995;16( Suppl 4): 54–65
   Google Scholar
• The Writing Group for the PEP Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. J Am Med Assoc 1995;273:199–208
   Google Scholar
• Vikhlyaeva EM, Zaidieva YaZ, Lobova TA, Shishkina AV, Larsen S. Trisequens in perimeno- pausal women with climacteric syndrome: a ran-domised double-blind trial. Acta Obstet Gynecol Scand 1997;76:1675(abstr P86.19)
   Google Scholar
• MacLennan A, Lester S, Moore V. Oral oestrogen replacement therapy versus placebo for hot flushes. Cochrane Database Syst Rev 2001;1: in press
   Google Scholar
• Nachtigall LE, Nachtigall LB. The effects of isoflavones derived from red clover on vasomotor symptoms and endometrial thickness. Proceed-ings of the Ninth International Menopausal Society World Congress on the Menopause. Climacteric 1992;2( Suppl 1):128
   Google Scholar
• Speroff L, Rowan J, Symons J, Genant H, Wilborn W. The comparative effect on bone density, endometrium, and lipids of continuous hormones as replacement therapy (CHART study). A randomized controlled trial. J Am Med Assoc 1996;17:1397–404
   Google Scholar
• Helton ED, Goldzieher JW. Pharmacokinetics of ethinyl estrogens: a review. Contraception 1981; 15:255–84
   Google Scholar
• MacLennan AH, MacLennan A, Wenzel S, Chambers H, Eckert K. Continuous low-dose oestrogen and progestogen hormone replacement therapy: a randomised trial. Med J Aust 1993; 159:102–6
   Google Scholar
• Norman RJ, Flight, HK, Rees MCP. Oestrogen and progestogen hormone replacement therapy for pen-menopausal and post-menopausal women: weight and body fat distribution. The Cochrane Library Oxford: Update Software, 1999:1
   Google Scholar